Plutonium-239 ion (Pu-239)

Plutonium-239 is a radioactive isotope of the actinide element plutonium, primarily known for its use in nuclear weapons and reactors. In a biological context, it is a potent toxicant and carcinogen rather than a physiological target like a receptor or enzyme (ATSDR, 2010). Once internalized via inhalation, ingestion, or wound contamination, plutonium-239 ions tend to deposit in the skeleton and liver (CDC, 2014). These ions emit high-energy alpha particles that cause significant DNA damage and increase the risk of cancers such as osteosarcoma and liver cancer (IARC, 2012). Because of its long biological half-life and high radiotoxicity, medical intervention focuses on decorporation therapy. This is achieved using chelating agents like Ca-DTPA and Zn-DTPA, which facilitate the mobilization and renal excretion of the plutonium ions (FDA, 2004). The chemical behavior of plutonium in the body often mimics that of iron, allowing it to be transported by transferrin to various tissues. Management of exposure is a critical concern in nuclear medicine and occupational safety.

Other names

Plutonium-239239PuPu-239 ion

Chelation therapy: Chelating agents like DTPA bind to the plutonium ion to form a stable, water-soluble complex that is excreted by the kidneys (FDA, 2004).